<analysis>
**Action 1 (obfuscation memo, RSP rule, paper, protocol, environments, data addendum).** The memo itself is routine internal work. The negative result is also well understood by now, which removes the reason the leads held back the replication protocol in January.
- Friction points:
  - An RSP-level rule binds several teams, and leadership tends to soften such rules to "guidance."
  - Securities counsel has vetoed disclosure-adjacent items two months running.
  - Moving the synthetic environments from 40% to 80% in about six weeks is ambitious, though agent-heavy teams can plausibly do it.
  - Opt-in addendum language needs commercial and legal drafting cycles.
- A generic methods paper with no incident rates has a decent chance of clearing counsel.
- The press and counsel-pull risk sits in Threat 4 and is not counted here.
- Many sub-parts mean partial success is the likely mode.

**Action 2 (bill introduction).** Per judge feedback, a new-Congress bill hitting its late-February introduction date is less likely than not.
- Offices add scope demands, and legislative counsel drafting takes weeks.
- The player's explicit no-preemption floor adds friction with Senate Republicans. The specific preemption split is Threat 2, not counted here.
- Generic scheduling slip is counted here.
- The DFS comment and Anthropic's endorsement are easy to deliver. Endorsement only matters if the bill is introduced.

**Action 3 (three-lab taxonomy and pilot).** Finalising taxonomy v1 with Google DeepMind and Microsoft is feasible, since both responded positively.
- A live sharing pilot needs data-sharing agreements reviewed by three sets of counsel. That usually takes more than one month.
- The March announcement is plausible only for the taxonomy.
- FMF politics sits in Threat 3.

**Action 4 (in-tenancy hospital scanning).** Hospital security and procurement reviews run for months, and pilot agreements signed in February are unlikely.
- Anthropic's own staged cyber-access policy and the Q2 KYC gap create a prerequisite problem. The cyber-capable tier is Glasswing-gated, and Fable routes cyber requests to Opus. This partly overlaps Threat 1, so I split them:
  - Threat 1 covers the compliance and eligibility finding.
  - The action covers the procurement pace and the internal access-policy decision.
- The OSS opt-in form and the respectful note about curl are easy.

**Action 5 (labour and science).** Parts that are easy or product-level:
- The monthly tracker is routine.
- The course-catalogue integration is product work.

Parts that are slow or aggressive:
- State agency deals move at procurement speed. The adversary's point about AI-in-hiring laws is real, but only leadership approval of the *offer* is needed this month.
- A March open-data release from a program started in January is aggressive but possible for computational outputs such as target prioritisation.

**Action 6 (proposals).** These are internal proposals with a low bar. Risks:
- Leadership may defer the compute-verification R&D funding.
- The track-2 workshop is still unconfirmed.
- The continual-learning research line is small and likely to be approved.

**Threats.**
- *Threat 1:* Restricted cyber capability is not on Bedrock at all, which makes the eligibility and weaker-model outcome fairly likely.
- *Threat 2:* Preemption is the central fault line in every federal AI bill, and the player invited it with the no-preemption floor.
- *Threat 3:* A three-lab carve-out inside an existing six-member agreement is a real friction point. It can also be framed as a working group.
- *Threat 4:* The press prong needs the paper actually released in February. The "guidance" dilution prong is independent and fairly plausible.
- *Threat 5:* There are two independent release candidates in-window (Gemini 4 GA in Q1 and the overdue DeepSeek V5). Kaplan has already cited competitors twice. Per the judge's instruction, I price this near that prior.
</analysis>

<action_odds>
Action 1 [Obfuscation memo + RSP rule + paper/protocol]: P(failure) 40%. Reason: The memo and protocol are straightforward, but the RSP rule, counsel clearance of the paper, the environment build target and the data addendum each carry friction. The likely outcome is a partial.

Action 2 [Bill introduction with safe harbor]: P(failure) 50%. Reason: A new-Congress bill often slips on legislative counsel drafting and scope additions. Late February is a tight target. The preemption split is excluded and counted in Threat 2.

Action 3 [Three-lab taxonomy and sharing pilot]: P(failure) 40%. Reason: The taxonomy v1 is likely to be finalised. A functioning sharing pilot needs three-company counsel sign-off within a month, which is unlikely.

Action 4 [In-tenancy hospital scanning]: P(failure) 55%. Reason: Health-system procurement and security review take months, and Anthropic's internal access policy blocks restricted cyber capability until KYC is in place. The OSS opt-in part is easy.

Action 5 [Workforce tools, tracker, disease data]: P(failure) 35%. Reason: The tracker and product integration are routine. State deals won't close this month, but leadership approval of the offer is achievable. The March data release is aggressive but computational.

Action 6 [Compute verification and stable-identity proposals]: P(failure) 30%. Reason: These are internal proposals with a low bar. Funding the verification R&D with RAND or academic partners may be deferred, and the workshop venue is still unconfirmed.
</action_odds>

<threat_odds>
Threat 1 [Bedrock HIPAA/cyber-tier gap]: P(materialises) 50%. Adversary suggested 55%; reason for any difference: The cyber tier is Glasswing-gated rather than on Bedrock, so this outcome is likely. I shade it slightly down because I am less sure of the model-level HIPAA exclusion claim, and because Opus-based scanning still yields something.

Threat 2 [Preemption split / introduction slip]: P(materialises) 40%. Adversary suggested 45%; reason for any difference: Preemption is the central fault line, and the player's floor provokes it. General slip is already counted in Action 2, so I avoid double-counting it here.

Threat 3 [FMF carve-out backlash]: P(materialises) 35%. Adversary suggested 40%; reason for any difference: The concern is real given the six-member agreement and Microsoft's ties to OpenAI. However, the pilot can be relabelled as an FMF working group, and OpenAI keeps a standing invitation.

Threat 4 [Obfuscation headline / RSP rule diluted]: P(materialises) 30%. Adversary suggested 35%; reason for any difference: The press prong needs the paper released in February, and prior literature reduces its novelty. The dilution prong is independent and moderately likely, which keeps the combined figure near 30%.

Threat 5 [Competitor/open-weight release squeeze]: P(materialises) 40%. Adversary suggested 35%; reason for any difference: Two independent release candidates fall in-window, and leadership has already twice cited competitors when limiting safety compute. That restated prior warrants slightly higher odds.
</threat_odds>
